TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has arranged a non-brokered private placement offering of 1,058,823 common shares priced at $0.85 per common share (the “Common Shares”), for gross proceeds of $900,000 CAD (the “Offering”). The proceeds of the Offering will be used by Arch to begin onboarding clinical sites in the U.S. for the Company’s Phase II trial for LSALT peptide targeting cardiac surgery-associated acute kidney injury, to accelerate pre-clinical studies for ...

TORONTO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that it has received central Institutional Review Board (“IRB”) approval of the protocol and related study documents for the Company’s ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”). Arch recently announced that the Company will expand the study into the United States following interest from clinicians at five leading institutions. The central IRB approval completes an important step toward activating these U.S. sites. It provides an ...

TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting cardiac surgery-associated acute kidney injury (“CS-AKI”) into the United States, following interest from clinicians at five leading U.S. institutions. The planned U.S. expansion builds on progress at the four Canadian clinical sites currently participating in the trial and patient data collected from the five sites in Turkey that were the first to recruit patients to the study. Patient ...